Insider Selling: Moderna, Inc. (NASDAQ:MRNA) President Sells 291 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 291 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $12,451.89. Following the completion of the sale, the president now owns 1,443,567 shares of the company’s stock, valued at $61,770,231.93. This trade represents a 0.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stephen Hoge also recently made the following trade(s):

• On Tuesday, September 3rd, Stephen Hoge sold 318 shares of Moderna stock. The stock was sold at an average price of $76.99, for a total transaction of $24,482.82.

Moderna Stock Up 2.8 %

Shares of NASDAQ MRNA traded up $1.20 during midday trading on Monday, hitting $44.26. 6,740,633 shares of the company’s stock were exchanged, compared to its average volume of 4,892,647. The firm’s fifty day simple moving average is $52.38 and its 200-day simple moving average is $90.84. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market cap of $17.03 billion, a PE ratio of -7.40 and a beta of 1.69. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the prior year, the business posted ($1.39) EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. Research analysts predict that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Analyst Ratings Changes

MRNA has been the subject of several research analyst reports. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. TD Cowen lowered their price target on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. The Goldman Sachs Group reduced their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Finally, Sanford C. Bernstein started coverage on shares of Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $83.33.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently made changes to their positions in MRNA. Inspire Trust Co. N.A. grew its position in Moderna by 73.5% during the 3rd quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company’s stock worth $1,104,000 after purchasing an additional 7,000 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Moderna by 1.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company’s stock valued at $19,239,000 after acquiring an additional 3,978 shares during the period. Toronto Dominion Bank raised its stake in Moderna by 23.7% during the 3rd quarter. Toronto Dominion Bank now owns 131,477 shares of the company’s stock valued at $8,787,000 after acquiring an additional 25,177 shares during the last quarter. Geode Capital Management LLC lifted its position in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after acquiring an additional 178,115 shares during the period. Finally, Groupama Asset Managment grew its stake in shares of Moderna by 29.1% in the 3rd quarter. Groupama Asset Managment now owns 21,838 shares of the company’s stock valued at $1,459,000 after purchasing an additional 4,920 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.